Switzerland· 66424002
Kevzara 200 mg/1.14 ml, solution pour injection en seringue préremplie
A sarilumab product, registered in Switzerland by Sanofi-Aventis (Suisse) SA and dispensed under Swissmedic category B. The same ATC class is registered in 13 of our 19 countries.
Checked against the register on
Informational only — not a medical device.
Where it is registered
Sarilumab is registered in 13 of 19 countries.
Countries holding a registration under ATC L04AC14 (sarilumab), each read from that country’s own register.
- This record: Switzerland
- 8 of them publish a price we can compare per daily dose
Sarilumab · ATC L04AC14
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of sarilumab costs, country by country.
Normalised to the WHO defined daily dose (14.3 mg), so markets compare like for like.
- Switzerland: $60.91 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Sarilumab · price per daily dose (14.3 mg)
USD · FX 28 Sept 2026
- CH Switzerland$60.91
The record
At a glance
- Manufacturer
- Sanofi-Aventis (Suisse) SA
- Country
- Switzerland (CH)
- ATC code
- L04AC14
- ATC class
- Sarilumab
- Defined daily dose
- 14.3 mg, P
- Swissmedic category
- B
- Reimbursed
- No
- Last checked
- June 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
190 interactions on record for sarilumab.
Graded by severity as the source publishes them — 39 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Sarilumab · interactions on record
190 records
- 39 severe
- 144 moderate
- 7 minor
Most severe, free to view
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- CladribineL01BB04severe
- PexidartinibL01EX15severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L04AC14
Sarilumab, as other registers publish it.
- FinlandKevzaraSanofi Winthrop Industrie
- FinlandKevzaraSanofi Winthrop Industrie
- DenmarkKevzaraSanofi Winthrop Industrie
- FinlandKevzaraSanofi Winthrop Industrie
- DenmarkKevzaraSanofi Winthrop Industrie
- FinlandKevzaraSanofi Winthrop Industrie
- FinlandKevzaraSanofi Winthrop Industrie
- PolandKevzaraSanofi Winthrop Industrie
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bbfc4b70-8168-49e0-a88e-eec9775da7c5 GET /v1/drugs/bbfc4b70-8168-49e0-a88e-eec9775da7c5?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "swissmedic_auth",
"heilmittelcode": "Biotechnologika"
}See everything about sarilumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.